PE CE JUN 0 1 200 E SPRESS MAIL NO.: EV 447409173 US DATE DEPOSITED: JUNE 1, 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Paul H. Weigel et al.) Atty. Dkt.	No.:	5820.603
Serial No.:	09/842,930)		
Filed:	April 25, 2001))		
	URONAN RECEPTOR ENDOCYTOSIS	,))		

MAIL STOP - FEE AMENDMENT Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT FILED UNDER 37 CFR 1.98(c)(1)

06/03/2004 LWDNDIM1 0000010% 09842930

01 FC:1806

180.00 DA

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- 1. **[X]** Statement Under 37 CFR 1.98(c)(1).
- 2. [X] Preliminary Statements
- 3. **[X]** FORM PTO/SB/08A AND 08B (formerly Form PTO-1449)
- 4. **[X]** Copies of Listed Information Items Accompanying this Statement
- 5. **[X]** Identification of Person(s) Making this Supplemental Information Disclosure Statement

06/93/2004 LUDNDIN1 00000105-041700 09

09842930

∕62 FC:2252

5820.603 Supp IDS.wpd

Section 1. Statement Under 37 CFR 1.98(c)(1)

Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement.

Section 2. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 3. FORM PTO/SB/08A AND 08B (formerly Form PTO-1449)

- [X] A completed Form PTO/SB/08A and/or 08B is attached hereto.
- [] No Form PTO/SB/08A and/or 08B is attached.

Section 4. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO/SB/08A And 08B (Modified) accompany this information disclosure statement.

Section 5. Identification of Person(s) Making This Information Disclosure Statement

The person making this statement is the attorney/agent who signs below on the basis of the information:

- [] supplied by the inventor(s)
- [] supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)).
- [X] in the attorney/agent's file

Respectfully submitted,

Kathryn L. Hester, Ph.D. Registration No. 46,768

DUNLAP, CODDING & ROGERS, P.C.

Customer Number 30589

P.O. Box 16370

Oklahoma City, Oklahoma 73113

Telephone: (405) 607-8600 Facsimile: (405) 607-8686

E-mail: kathryn_hester@okpatents.com

Web Site: www.okpatents.com

Agent for Applicants

Express Mail:

EV 447409173 US

Date Deposited: 06/17/2004

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	09/842,930			
Filing Date	04/25/2001			
First Named Inventor	Paul H. Weigel et al.			
Group Art Unit	1647			
Examiner Name	L. Spector			
Attorney Docket Number	5820.603			

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	5,206,353		Berger, et al.	04/27/1993		
	AB	5,696,237		Fitzgerald, et al.	12/09/1997		
	AC	6,060,037		Waldman	05/09/2000		
					ļ		
					ļ		
	-						
					 		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Office	Foreign Patent Do Number ⁴	Cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆	
	AD	wo	02 059315 A		Curagen Corp.	08/01/2002	1-27	_	
								ļ	
								╁	
		 							
		ļ						-	
		 						+	
-		\vdash				† 			

Examiner		Date	
Signature	İ	Considered	

Mail Stop IDS, Comm. for Patents

SEND TO:

PO Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

EV 447409173 US

06/17/2004

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

JUN 0 1 2004 Sulling S

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known				
Application Number	09/842,930			
Filing Date	04/25/2001			
First Named Inventor	Paul H. Weigel et al.			
Group Art Unit	1647			
Examiner Name	L. Spector			
Attorney Docket Number	5820.603			

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	AE	ZHOU, B. ET AL.: "Identification of the hyaluronan receptor for endocytosis (HARE)." The Journal of Biological Chemistry; US, Vol. 275, No. 48; 08/21/2000; pp 37733-37741; XP002273598 ISSN: 0021-9258					
	AF	OHARA, O. ET AL.: "The nucleotide sequence of a long cDNA clone isolated from human spleen". Database accession no. AK024503 XP002273599					
	AG	BANERJI SUNEALE ET AL.: "LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan". The Journal of Cell Biology, Rockefeller University Press, US, Vol. 144, No. 4, 02/22/1999, pp. 789-801, XP002159438 ISSN: 0021-9525					
	АН	DUFF, B. et al., "Endothelium in hepatic cavernous hemangiomas does not express the hyaluronan receptor for endocytosis", Human Pathology, March 2002, Vol. 33, No. 3, pages 265-269.					
	AI	ZHOU, B. et al., "Purification and molecular identification of the human hyaluronan receptor for endocytosis", Glycobiology, 01 May 2003, Vol. 13, No. 5, 339-349.					
	AJ	ZHOU, B. et al., "Purification and subunit characterization of the rat liver endocytic hyaluronan receptor", J. Biol. Chem. 26 November 1999, Vol. 274, No. 48, pages 33831-33834, especially page 33832, column 2.					

	r	
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.